ArticleBMC pediatrics2026
Thymic evolution on serial CT in glucocorticoid-treated pediatric pneumonia: a retrospective analysis.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe pediatric thymus is sensitive to infection-related stress and glucocorticoid exposure, yet data remain limited on short-term thymic changes on paired chest CT before and after glucocorticoid-containing treatment for childhood pneumonia. This study evaluated changes in thymic transverse and anteroposterior diameters and CT attenuation on paired chest CT scans.
methodsWe retrospectively included 90 children with pneumonia who received glucocorticoid-containing therapy and had paired chest CT scans. Two radiologists independently measured the thymic transverse diameter, anteroposterior diameter, and CT attenuation before and after treatment. We used the Wilcoxon signed-rank test to compare pre- and post-treatment thymic parameters, and used age-stratified analysis, Spearman correlation, and multivariable linear regression to explore factors associated with thymic percentage changes.
resultsAfter treatment, thymic transverse diameter decreased from 2.80 cm to 2.40 cm, anteroposterior diameter decreased from 1.20 cm to 0.70 cm, and CT attenuation decreased from 50.00 HU to 37.50 HU; all three parameters were significantly lower after treatment (all P < 0.001). Age-stratified analysis showed that each age group experienced significant reductions in these parameters, with no significant between-group differences in percentage changes. Dose-related analysis showed that cumulative methylprednisolone-equivalent dose and daily methylprednisolone-equivalent dose were weakly negatively correlated with the percentage change in thymic transverse diameter. However, multivariable linear regression indicated that dose metrics were not significantly associated with percentage changes in thymic transverse diameter, anteroposterior diameter, or CT attenuation.
conclusionIn children with pneumonia receiving glucocorticoid-containing treatment, short-term follow-up CT showed reductions in thymic transverse diameter, anteroposterior diameter, and CT attenuation. Recognizing these possible short-term thymic changes may help pediatricians and radiologists avoid overinterpreting follow-up CT findings as anterior mediastinal lesions.Given the lack of a non-glucocorticoid control and the potential for severe pneumonia to induce thymic involution, causality cannot be inferred. Thus, thymic CT changes are not validated biomarkers of glucocorticoid exposure or immune function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.